GlassScriptPhysician profile
Christopher K Hwe
NPI 1790149136
$3,740.21
in general payments reported to CMS, 2019-2025
32 companies · $1,777 in 2025
The $1,777 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $208 · 2024: $1,755 · 2025: $1,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,556 · Education: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,556.12 |
| Education | $184.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $615.68 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $438.11 | 2023-2025 | Breztri, Tezspire, Airsupra |
| Merck Sharp & Dohme LLC | $339.22 | 2023-2025 | Winrevair, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $280.64 | 2023-2025 | Ofev, Jardiance, Jascayd |
| Insmed, INC. | $185.82 | 2024-2025 | Arikayce |
| Lilly USA, LLC | $166.09 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Regeneron Healthcare Solutions, INC. | $158.18 | 2024-2025 | Dupixent |
| Viatris Specialty LLC | $153.45 | 2025 | Yupelri |
| Electromed, INC. | $144.67 | 2024-2025 | Smartvest |
| United Therapeutics Corporation | $141.35 | 2024-2025 | Tyvaso, Tyvaso |
| Novo Nordisk INC | $123.71 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Mylan Specialty L.P. | $114.99 | 2023-2024 | Yupelri |
| Genzyme Corporation | $104.66 | 2024 | |
| Sanofi-Aventis U.S. LLC | $94.95 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $90.33 | 2024-2025 | Glassia |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $90.11 | 2025 | Ohtuvayre |
| Amgen INC. | $54.95 | 2023-2025 | Tezspire, Tavneos |
| Philips North America LLC | $46.80 | 2024-2025 | Vest Therapy Und, (Ak6) Vest Therapy |
| Boston Scientific Corporation | $46.21 | 2025 | Watchman Flx |
| Paratek Pharmaceuticals, INC. | $45.44 | 2024-2025 | Nuzyra |
| Abiomed | $42.86 | 2023-2024 | Impella |
| Vifor Pharma, INC. | $36.93 | 2024 | Zemaira, Veltassa |
| Ani Pharmaceuticals, INC. | $34.58 | 2025 | Purified Cortrophin Gel |
| Pfizer INC. | $30.36 | 2024-2025 | |
| Inspire Medical Systems, INC. | $28.20 | 2024 | Inspire |
| Grifols USA, LLC | $24.73 | 2025 | Prolastin-C Liquid |
| Pulmonx Corporation | $23.66 | 2025 | Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Chartis Catheter |
| Abbvie INC. | $21.04 | 2023 | |
| Zoll Respicardia, INC. | $16.96 | 2025 | Remede System |
| Exact Sciences Corporation | $15.48 | 2024 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $15.18 | 2024 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $14.87 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hwe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.